Genome-Wide CRISPR Screening Service
Creative Biolabs offers a specialized genome-wide CRISPR screening service, leveraging the precision of CRISPR knockout (CRISPRko) technology to systematically explore gene functions across the genome. Using sgRNA libraries to induce targeted gene disruptions, CRISPRko screens help identify genes critical for phenotypes like drug resistance, cell viability, and proliferation. This high-throughput approach is essential for discovering therapeutic targets, mapping biological pathways, and advancing functional genomics. Compared to RNAi, CRISPRko ensures greater specificity and efficiency. We provide comprehensive solutions—from CRISPR library design to data analysis—empowering your research in oncology, infectious disease, and beyond with reliable, high-impact results.
Introduction of Genome-Wide CRISPR Screening Service
Genome-wide CRISPR knockout (CRISPRko) screening is a powerful tool in functional genomics, enabling large-scale, systematic disruption of genes to investigate their roles in various biological processes, via integrating high-coverage sgRNA libraries, efficient lentiviral delivery, and comprehensive bioinformatics analysis. The technology is based on the CRISPR-Cas9 system, where a sgRNA directs Cas9 to a specific genomic site, inducing a double-strand break. This is repaired through NHEJ, often resulting in frameshift mutations that cause permanent gene knockout. CRISPRko libraries offer comprehensive genome-wide coverage, targeting all protein-coding genes with couples of sgRNAs per gene to ensure high knockout efficiency and low off-target effects. Applications of CRISPRko screening include identifying essential genes in cancer, discovering drug resistance mechanisms, and exploring gene function in cell differentiation, signaling, and metabolism—supporting both basic research and therapeutic innovation.
Figure 1. Application of genome wide CRISPR screens in various infectious diseases: the genome wide CRISPR screens can discover host factors which aid in viral attachment, entry into cell, release of viral content and integration into nucleus and lastly formation and release of viral particles.1
CRISPR Knockout (CRISPRko) vs. RNA Interference (RNAi): The Superior Choice
For years, RNA interference (RNAi) via short hairpin RNAs (shRNAs) was the gold standard for large-scale genetic screening. However, the advent of CRISPRko has systematically redefined the boundaries of accuracy.
- Complete Ablation vs. Partial Knockdown: RNAi relies on the degradation of messenger RNA (mRNA). This process is rarely 100% efficient, resulting in a "knockdown" rather than a true "knockout." Residual protein expression can easily mask critical phenotypes, leading to false negatives. CRISPRko, conversely, permanently alters the genetic code via frameshift mutations, completely eliminating protein expression.
- Off-Target Effects: RNAi is notorious for severe off-target effects. Short seed sequences in shRNAs can inadvertently bind and degrade hundreds of unintended transcripts, confounding the final data. While CRISPR off-target effects exist, meticulous sgRNA design protocols and the inherent specificity of the Cas9/PAM interaction have dramatically reduced these events to near negligible levels in pooled screening formats.
- Nuclear Targets: RNAi is primarily active in the cytoplasm, making it highly inefficient at targeting non-coding RNAs or strictly nuclear proteins. CRISPR operates directly on the genomic DNA in the nucleus, making it universally applicable to any genetically encoded element.
Compared to RNAi, CRISPRko definitively ensures much greater specificity and significantly higher efficiency, making it the undisputed platform of choice for modern functional genomics.
Practical Recommendation
| Project Goal | Most Suitable Screening Method |
|---|---|
| Unbiased discovery of genes controlling a phenotype | Genome-Wide CRISPR Screening |
| Finding genes whose activation produces a phenotype | CRISPRa Screening |
| Studying gene repression without permanent knockout | CRISPRi Screening |
| Understanding how perturbations affect cell states at single-cell resolution | Single-Cell CRISPR Screening |
| Discovering drug resistance genes | Genome-Wide CRISPR Screening or CRISPRa Screening |
| Identifying essential or growth-dependent genes | Genome-Wide CRISPR Screening or CRISPRi Screening |
| Mapping pathway regulators through reporter activity | Genome-Wide CRISPR Screening, CRISPRa Screening, or CRISPRi Screening |
| Studying heterogeneous immune, stem cell, or disease models | Single-Cell CRISPR Screening |
How Genome-Wide CRISPR Screening Service Can Assist Your Project
At Creative Biolabs, our genome-wide CRISPR screening service follows a rigorous and well-validated workflow designed to ensure accuracy, reproducibility, and meaningful outcomes. From high-quality sgRNA library preparing and precise lentiviral packaging, to virus infection optimization, screening execution, and deep sequencing, every step is carried out under strict quality control standards. Our comprehensive bioinformatics analysis interprets the screen results with high precision, identifying significantly enriched or depleted sgRNAs that point to key genes involved in your phenotype of interest. This powerful approach enables you to uncover essential genes, regulators of drug resistance, novel therapeutic targets, and critical components of biological pathways. Whether you're working on cancer biology, infectious disease, stem cell research, or drug development, our service provides actionable data to drive your research forward.
Advanced CRISPR Screening Solutions
While standard genome-wide knockout screening is our most popular offering, our technical portfolio extends far beyond basic disruption. We offer a comprehensive suite of highly specialized screening modalities tailored to uniquely complex biological questions.
Custom Sub-Library Screening
Not every project requires querying the entire genome. We frequently design and execute custom targeted libraries focused on specific functional domains. Common highly specialized screens include:
- Kinase Knockout Screening
- Epigenetic Gene Knockout Screening
- Membrane Protein Knockout Screening
- Transcription Factor Knockout Screening
- Metabolic Gene Knockout Screening
- Apoptosis related Gene Knockout Screening
Workflow of Genome-Wide CRISPR Screening Service
Figure. 2 Workflow of our genome-wide CRISPR screening service.
Critical Design Considerations for a Successful Screen
01 A Clear and Measurable Phenotype
The success of a genome-wide CRISPR screen depends heavily on the quality of the phenotype. Strong screens are built around phenotypes that are measurable, reproducible, and linked to the biological question. Creative Biolabs helps clients evaluate whether a phenotype is suitable for pooled screening or whether a pilot assay is needed.
02 Appropriate Cell Model Selection
Cell type can strongly influence screening results. A gene that is essential in one model may be dispensable in another. Creative Biolabs helps clients evaluate whether their selected cell model is compatible with CRISPR editing, lentiviral delivery, expansion, selection, and downstream readout.
03 Sufficient Library Coverage
Loss of library coverage can lead to unreliable results. Maintaining adequate cell numbers throughout transduction, selection, passaging, and sample collection is essential. Creative Biolabs designs workflows to preserve representation and reduce bottlenecks.
04 Optimized Selection Pressure
Selection conditions must be strong enough to reveal meaningful differences but not so harsh that the population collapses. Drug concentration, treatment duration, infection dose, sorting threshold, and culture period should be carefully optimized.
Why Choose Us?
- High-Coverage sgRNA Libraries - The libraries cover all protein-coding genes in genome level with 4–6 sgRNAs per gene, ensuring high knockout efficiency and reliable screening results.
- Optimized Lentiviral Delivery System - Mature lentiviral packaging enables efficient Cas9 integration and stable sgRNA delivery across various cell types.
- Strict Quality Control & Robust Data Analysis - Every step—from library prep to analysis—is tightly controlled. Our bioinformatics pipeline provides accurate hit identification and clear biological insights.
- Flexible Screening Strategies - Supports various levels of library design and customizable experimental workflows to accommodate diverse research objectives and project requirements.
- Affordable Pricing & Excellent Support - Competitive pricing with responsive, professional support ensures a smooth project experience from start to finish.
Our Streamlined Collaboration Process: From Concept to Discovery
We believe that a successful genome-wide CRISPR screen is built on a foundation of absolute transparency, rigorous scientific communication, and true partnership. To ensure a seamless experience and the highest quality data, we have developed a highly structured, milestone-driven collaboration workflow. From your first inquiry to the final data walkthrough, our dedicated project managers and senior scientists are with you every step of the way.
Phase 1: Initial Consultation & Scientific Needs Assessment
Every great discovery starts with a conversation. When you reach out to us, we schedule a free, in-depth technical consultation with our senior CRISPR specialists.
Phase 2: Custom Strategy Design & Proposal Generation
Based on our consultation, our scientific team designs a meticulously customized screening strategy. We will provide you with a comprehensive, transparent Statement of Work (SOW) and a detailed project proposal. This document thoroughly outlines the entire experimental design, the specific sgRNA library to be used, quality control checkpoints, detailed timelines, and a highly competitive, straightforward pricing structure with no hidden fees.
Phase 3: Project Initiation & Pre-Screening Optimization
If you are providing a proprietary cell line, we first perform strict Quality Control (QC), including mycoplasma testing and viability checks. If you are providing a proprietary cell line, we first perform strict Quality Control (QC), including mycoplasma testing and viability checks.
Phase 4: Screening Execution & Milestone Reporting
As we move into the large-scale library transduction and the application of selective pressures, we do not leave you in the dark. We operate with a "no black box" philosophy. Your project manager will provide regular, scheduled milestone reports outlining the progress of cell expansion, selection efficiency, and genomic DNA harvesting.
Phase 5: Sequencing, Bioinformatics Analysis & Data Delivery
Following the precise execution of the screen, we proceed to high-depth Next-Generation Sequencing (NGS) and our proprietary bioinformatics pipeline. Upon completion, we deliver a highly secure, comprehensive data package.
Frequently Asked Questions (FAQ)
Q: What types of cell lines are compatible with this service?
A: We have extensive experience with a vast array of immortalized adherent and suspension cell lines, as well as complex patient-derived models. The primary requirement is that the cells can be efficiently transduced with lentivirus and cultured in sufficient numbers to maintain proper library representation.
Q: Why is maintaining library coverage (representation) so critical?
A: If coverage drops too low, certain sgRNAs may be lost purely due to random chance (bottlenecking) rather than biological selection. We strictly maintain a minimum coverage of 500x to 1000x—meaning there are 500 to 1000 individual cells harboring each specific sgRNA in the library. This massive redundancy is mathematically required to eliminate background noise and ensure robust statistical power.
Q: Can you perform CRISPR screens on non-human cells?
A: Yes. While human and murine libraries are standard off-the-shelf options, we feature advanced capabilities for custom CRISPR screening. We can computationally design, synthesize, and execute genome-wide or highly targeted screens for practically any organism with a fully sequenced reference genome.
Q: What kind of data report will I receive at the end of the project?
A: You will receive an extremely comprehensive, publication-ready data package. This includes raw sequencing files (FASTQ), highly detailed read count matrices, robust statistical hit-ranking tables, visually striking publication-quality graphics (including volcano plots, scatter plots, and heatmaps), and extensive biological pathway enrichment analyses to deeply interpret the functional relevance of your specific top genetic hits.
Q: Do you offer validation services for the "hits" identified in the screen?
A: Absolutely. Identifying hits is only phase one. We offer comprehensive follow-up services utilizing our robust CRISPR assisted Cell Line Development platform. We can rapidly generate highly pure, single-cell derived knockout or knock-in clonal lines for any top candidate gene to empirically validate the screening data through secondary functional assays.
Conclusion and Call to Action
Let us comprehensively help you accelerate your discovery with unparalleled confidence. Do not let technical bottlenecks slow your pursuit of the next major therapeutic breakthrough. Contact us today to deeply discuss how our genome-wide CRISPR screening service can be perfectly tailored to intricately meet your highly specific scientific goals and fundamentally transform your research pipeline.
Reference
- Srivastava K, Pandit B. Genome-wide CRISPR screens and their applications in infectious disease. Frontiers in Genome Editing, 2023, 5: 1243731. https://doi.org/10.3389/fgeed.2023.1243731 Distributed under Open Access license CC BY 4.0, without modification.
